Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Syngene International, a subsidiary of Biocon, is a contract research, development and manufacturing organization (CRDMO) providing discovery chemistry and biology, preclinical and clinical development, and commercial-scale manufacturing (small molecules and biologics) to global pharma, biotech and agrochemical clients. It runs dedicated research centres for clients such as Bristol Myers Squibb and Baxter, and has added US biologics capacity. Revenue is driven by long-term research collaborations and a growing manufacturing/CDMO mix.
It is India's largest listed contract research organization.
Syngene International Ltd. is a constituent of NIFTY 500, NIFTY HEALTHCARE, NIFTY SMALLCAP 100, NIFTY SMALLCAP 250, NIFTY SMALLCAP 50. See where it sits on the market heatmap →
Consolidated annual figures taken from Syngene International Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 7.87 | 12.35 | 12.71 |
| Book value / share (₹) | 120.11 | 117.44 | 105.91 |
| Return on equity | 6.5% | 10.5% | 12.0% |
| Return on capital employed | 8.5% | 11.3% | 11.8% |
| Operating margin | 12.4% | 16.7% | 16.9% |
| Net margin | 8.5% | 13.6% | 14.6% |
| EBITDA | ₹919 Cr | ₹1,042 Cr | ₹1,014 Cr |
| Free cash flow | ₹547 Cr | ₹398 Cr | ₹531 Cr |
| Total debt | ₹9 Cr | ₹120 Cr | ₹142 Cr |
| Debt to equity | 0.00 | 0.03 | 0.03 |
| Interest coverage | 9.5 | 11.5 | 12.5 |
| Current ratio | 1.38 | 1.64 | 1.71 |
| Shares outstanding | 40,29,00,000 | 40,25,00,000 | 40,20,00,000 |
Open the full income statement, balance sheet and cash flow for SYNGENE →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.